Helus reported that its psychedelic candidate (STAT+ account of the Phase 3 readout) produced statistically significant improvements in major depression, while serious adverse events raised safety questions. At six weeks, patients receiving the drug plus standard antidepressants improved by 19.5 points on the MADRS scale versus 11.9 points with placebo. At 12 weeks, the effect appeared largely maintained—16.9 points versus 9.9 in placebo—again with statistical significance. However, the report highlights that several serious adverse events in the study became a focal point for risk assessment. For developers and clinicians, the balance of effect size, durability, and tolerability will likely determine whether the program can progress through regulatory review or requires additional safety characterization.